Aanjaneya Lifecare Limited, India’s fastest growing Pharmaceutical Group having a proven track record of delivering consistence performances engaged in the manufacture of Active Pharmaceutical Ingredients and Finished Dosage Forms along with delivery of CRAMS has its presence in 60 countries in the fiercely competitive domestic Contract Manufacturing Market as well as in International market with a significant leadership market presence in Quinine Salts manufacturer in the world said today Aanjaneya Lifecare Limited, India’s fastest growing Pharmaceutical Group having a proven track record of delivering consistence performances engaged in the manufacture of Active Pharmaceutical Ingredients and Finished Dosage Forms along with delivery of CRAMS has its presence in 60 countries in the fiercely competitive domestic Contract Manufacturing Market as well as in International market with a significant leadership market presence in Quinine Salts manufacturer in the world , has acquired 100% stake in Fair Success Hong Kong and Dr. Datsons Labs, United Kingdom on 2013.
Aanjaneya Lifecare Limited, BSE code (533412), a Rs 490 crores, integrated pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients and Finished Dosage Forms along with delivery of CRAMS has its presence in 60 countries.
The company with its manufacturing facilities –in Mahad, Hyderabad and Pune has to its credit many achievements.
• It is the world’s third-largest manufacturer of quinine salts and the second-largest in India. Only nine companies globally manufacture quinine salts. Aanjaneya is only the second company to receive WHO prequalification for its anti-malarial APIs and formulations.
• It is one of the most cost-effective quinine manufacturers
• One of the largest codeine quota holders in the pharmaceutical sector
• The only manufacturer of multi- flavored Lozenge medical products in India
• The only company in India to be classified as ethical prescription dosages for diverse therapeutic segments. It is positioned as a global Centre of Excellence in the area of Lozenge manufacture
• The company pioneered the recognition that lozenges represent a stable platform for the delivery of pharmaceutical and nutraceutical ingredients
• Anjaneya’s Nicco Nil lozenge is a first-of-its-kind remedy in the world for smoking de-addition; its Relacs is a first-time lozenge against insomnia in India, and Arecta Plus, a lozenge variant for Viagra, is a first for India.
The company has an expertise in opportunity spotting and innovation. The company’s success has been built on a business model that integrates Research, Innovation and Knowledge. The company has invested in building proprietary Knowledge through research and acquisitions.
Anajaneyas Lifecare’s competence has been validated through patents granted by international and Indian authorities.
Positive:-
- Dr.Datsons Labs Ltd has informed BSE that the Company has successfully completed its obligations towards the FCCB Bond Holders for 40 Million USD. There is no Unpaid Debt by the Company towards Bondholders as on July 17, 2014.
- After FCCB conversion, promoter holding is 10 percentage, fii holding 56.79 and and other corporate bodies holding 23 percentage, so almost 90 percentage of shares with promoters n corporate bodies.. only 10 percentage shares with retail investors
- It Will show good quarterly results in future as large demand for their service and as debt came down.
- Currently more than rs.350 crore Asset in hand
- Book value of stock is above 65.38
- cmp 10.00
- Disc : It is safe to assume that I have vested interest in " Dr. DATSONS LABS ".
No comments:
Post a Comment